Muscle growth is one of the most common reasons people explore growth hormone-releasing peptides and secretagogues. The biological logic is straightforward: growth hormone (GH) and insulin-like growth factor 1 (IGF-1) play well-documented roles in protein synthesis, nitrogen retention, and muscle tissue development. Peptides that elevate endogenous GH production have been studied for their potential effects on body composition, including lean mass.
This review examines the peptides most studied for muscle growth applications, ranked by evidence strength. It also addresses WADA (World Anti-Doping Agency) status, as all growth hormone secretagogues are prohibited in competitive sport.
Important Note: WADA Prohibited Status
All growth hormone secretagogues and growth hormone-releasing peptides are on the WADA Prohibited List under Category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). This includes CJC-1295, Ipamorelin, MK-677, Tesamorelin, GHRP-2, GHRP-6, and all related compounds. Athletes subject to anti-doping testing should be aware that use of any of these compounds will result in a positive test and potential sanctions. This prohibition applies both in-competition and out-of-competition.
How GH Secretagogues Relate to Muscle Growth
Growth hormone secretagogues (GHS) stimulate the pituitary gland to release more of the body's own growth hormone. This differs from exogenous GH administration, which provides synthetic growth hormone directly. The GH released then stimulates the liver to produce IGF-1, which mediates many of GH's anabolic effects including:
- Stimulation of protein synthesis in skeletal muscle
- Enhancement of nitrogen retention
- Promotion of satellite cell activation and differentiation
- Increased collagen synthesis in tendons and connective tissue
- Lipolysis (fat mobilization), which may improve body composition independent of muscle gain
It is important to note that GH elevation through secretagogues produces more physiological GH pulses than supraphysiological exogenous GH dosing. This means the magnitude of effect on muscle growth may be more modest than what is seen with direct GH or anabolic steroid use.
1. CJC-1295 — Sustained GHRH Analog
CJC-1295 is a synthetic 30-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). Two forms exist: CJC-1295 with Drug Affinity Complex (DAC), which extends its half-life to approximately 6 to 8 days, and CJC-1295 without DAC (sometimes called Modified GRF 1-29), which has a half-life of about 30 minutes.
Mechanism
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating GH synthesis and release. The DAC version binds to serum albumin, dramatically extending its duration of action and producing sustained GH elevation rather than acute pulses.
What the Research Shows
A published clinical study in healthy adults demonstrated that CJC-1295 with DAC produced a 2- to 10-fold increase in GH levels and a 1.5- to 3-fold increase in IGF-1 levels that was sustained for up to 6 days after a single injection. These elevations were dose-dependent and consistent across subjects.
However, the critical distinction is between GH elevation and muscle growth. While the study confirmed potent GH stimulation, it was not designed to measure body composition changes. The connection between CJC-1295-induced GH elevation and actual muscle hypertrophy in humans relies largely on extrapolation from established GH physiology rather than direct demonstration in dedicated muscle growth studies.
Evidence Rating: Strong for GH Elevation, Indirect for Muscle Growth
2. Ipamorelin — Selective GH Secretagogue
Ipamorelin is a pentapeptide growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a) on pituitary cells. It is notable for being one of the most selective GHRPs studied, meaning it elevates GH without significant effects on cortisol, prolactin, or appetite compared to earlier secretagogues like GHRP-6.
Mechanism
Ipamorelin stimulates GH release through the ghrelin receptor pathway, which is distinct from and complementary to the GHRH pathway that CJC-1295 uses. This is why the two are frequently discussed as a combination: CJC-1295 amplifies GH synthesis through GHRH signaling while ipamorelin triggers acute GH release through ghrelin signaling.
What the Research Shows
Animal studies have demonstrated that ipamorelin produces dose-dependent GH release with high selectivity. Clinical studies have confirmed GH elevation in humans. One clinical study in postoperative patients showed that ipamorelin maintained positive nitrogen balance (an anabolic marker) compared to placebo, which is suggestive of muscle-sparing or anabolic effects.
The selectivity profile is a practical advantage. Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly stimulate appetite (via ghrelin pathways) or elevate cortisol, making it potentially more suitable for body composition goals where appetite and stress hormone management matter.
Evidence Rating: Moderate Clinical, Strong Selectivity Profile
3. MK-677 (Ibutamoren) — Oral GH Secretagogue
MK-677 is a non-peptide, orally active growth hormone secretagogue. While not technically a peptide, it acts through the same ghrelin receptor as peptide GHRPs and is frequently discussed alongside them. Its oral bioavailability and extensive clinical trial history make it one of the most-studied compounds in this category.
Mechanism
MK-677 mimics ghrelin at the GHS-R1a receptor, producing sustained GH and IGF-1 elevation with once-daily oral dosing. Studies have shown it maintains GH pulsatility (natural pulse patterns) while elevating overall 24-hour GH exposure.
What the Research Shows
MK-677 has the most extensive clinical data of any GH secretagogue. Notable findings include:
- Body composition study: A clinical trial in obese subjects demonstrated that MK-677 reversed diet-induced nitrogen wasting (catabolism), suggesting muscle-sparing effects during caloric restriction.
- Elderly study: A two-year study in older adults showed sustained IGF-1 elevation and increases in fat-free mass, though the clinical significance of the lean mass gains was modest.
- GH-deficient adults: Studies showed significant GH and IGF-1 increases comparable to injectable GH replacement in some measures.
Important caveats: MK-677 consistently increases appetite (a ghrelin-mediated effect), which can counteract body composition goals if caloric intake is not controlled. It may also affect fasting blood glucose and insulin sensitivity, particularly with long-term use. Water retention and mild extremity edema have been reported.
Evidence Rating: Strongest Clinical Data in Category, Notable Side Effects
4. Tesamorelin — FDA-Approved GHRH Analog
Tesamorelin is a synthetic GHRH analog that holds a unique position in this category: it is the only GH secretagogue with FDA approval (marketed as Egrifta). It is approved specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Mechanism
Like CJC-1295, tesamorelin acts on the GHRH receptor to stimulate endogenous GH release. Its mechanism for reducing visceral adipose tissue involves GH-mediated lipolysis and may involve modulation of adipokines and inflammatory markers associated with visceral fat.
What the Research Shows
Clinical trials supporting FDA approval demonstrated significant reductions in trunk fat (visceral adipose tissue) in HIV-associated lipodystrophy. Studies also reported modest increases in IGF-1 levels without supraphysiological GH elevation.
For muscle growth specifically, the evidence is limited. Tesamorelin trials focused on body fat reduction rather than lean mass accretion. Some secondary endpoints showed trends toward improved lean mass, but these were not the primary outcomes measured and were modest in magnitude. Its relevance to muscle growth is primarily through the GH-mediated mechanisms shared by all GHRH analogs.
Evidence Rating: Strong Clinical for Fat Reduction, Limited for Muscle Growth
Realistic Expectations: Peptides vs. Direct GH vs. Anabolic Steroids
Context matters when evaluating muscle growth claims for GH secretagogues. The magnitude of GH elevation from secretagogues is generally more modest and more physiological than from exogenous GH injections, which can produce supraphysiological levels. And even supraphysiological GH produces far more modest muscle hypertrophy than anabolic-androgenic steroids (AAS).
Published reviews comparing the muscle-building effects of GH versus AAS consistently show that GH alone produces modest lean mass changes, often attributable in part to water retention and connective tissue growth rather than pure contractile muscle hypertrophy. GH secretagogues, which produce lower GH elevations than exogenous GH, would be expected to produce even more modest effects.
This is not to say these peptides have no effect on body composition. The nitrogen balance data, the fat-free mass measurements, and the lipolysis effects are real and documented. But anyone expecting GH secretagogues to produce steroid-like muscle growth is likely to be disappointed.
Training and Nutrition Remain the Foundation
No peptide replaces progressive resistance training, adequate protein intake, sufficient sleep, and caloric management. These fundamentals account for the vast majority of muscle growth outcomes. GH secretagogues may potentially offer a modest additional contribution in the context of optimized training and nutrition, but they are not a substitute for these basics.
Summary Table
| Peptide | Route | GH Elevation | Direct Muscle Evidence | WADA Status |
|---|---|---|---|---|
| CJC-1295 | Injectable | Strong, sustained | Indirect (via GH) | Prohibited |
| Ipamorelin | Injectable | Moderate, selective | Nitrogen balance data | Prohibited |
| MK-677 | Oral | Strong, sustained | Modest FFM increases | Prohibited |
| Tesamorelin | Injectable | Moderate | Fat loss focus, limited muscle data | Prohibited |
Disclaimer
This article is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. All growth hormone secretagogues are on the WADA Prohibited List and are banned in competitive sport. Many peptides discussed are not approved by the FDA for muscle growth indications. Always consult a qualified healthcare professional before considering any peptide or supplement. PeptideWise does not sell peptides or endorse any vendor or source.